{"id":"ibritumomab-tiuxetan-maintenance","safety":{"commonSideEffects":[{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ibritumomab tiuxetan binds to the CD20 antigen expressed on B-cell lymphomas, and the tiuxetan chelator carries yttrium-90, a beta-emitting radioisotope that delivers localized radiation to tumor cells and surrounding tissue. The maintenance phase extends therapeutic benefit through repeated or continued dosing to sustain disease control.","oneSentence":"Ibritumomab tiuxetan is a radiolabeled monoclonal antibody that targets CD20 on B cells and delivers cytotoxic radiation directly to lymphoma cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:24.148Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory B-cell non-Hodgkin lymphoma"},{"name":"Follicular lymphoma (maintenance therapy)"}]},"trialDetails":[{"nctId":"NCT01827605","phase":"PHASE3","title":"A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)","status":"UNKNOWN","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2012-01","conditions":"Relapsed Follicular Lymphoma","enrollment":159},{"nctId":"NCT04189588","phase":"PHASE2","title":"Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine","status":"COMPLETED","sponsor":"TerSera Therapeutics LLC","startDate":"2020-03-25","conditions":"Oncology Patients Receiving Chemotherapy","enrollment":34},{"nctId":"NCT00168727","phase":"PHASE4","title":"Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Biogen","startDate":"2003-06-01","conditions":"Lymphoma, Non-Hodgkin, Lymphoma, Low-Grade","enrollment":12},{"nctId":"NCT02063685","phase":"PHASE3","title":"Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2012-07","conditions":"Follicular Non-Hodgkin's Lymphoma","enrollment":807},{"nctId":"NCT00290511","phase":"PHASE2","title":"Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2004-06-29","conditions":"Lymphoma","enrollment":49},{"nctId":"NCT01662102","phase":"PHASE3","title":"Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)","status":"TERMINATED","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2012-12-11","conditions":"Follicular Lymphoma","enrollment":1},{"nctId":"NCT00591630","phase":"PHASE2","title":"Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-11-14","conditions":"Diffuse Large Cell Lymphoma, Lymphoma","enrollment":30},{"nctId":"NCT00662948","phase":"PHASE2","title":"ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2008-12","conditions":"Lymphoma","enrollment":149},{"nctId":"NCT00582166","phase":"PHASE2","title":"Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance","status":"TERMINATED","sponsor":"University of Wisconsin, Madison","startDate":"2005-01-25","conditions":"Non-Hodgkin's Lymphoma","enrollment":18},{"nctId":"NCT01446562","phase":"PHASE2","title":"Y90 Ibritumomab Tiuxetan Post R-CHOP Chemotherapy for Advanced Stage Follicular Lymphoma","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2007-05","conditions":"Follicular Lymphoma","enrollment":34},{"nctId":"NCT00772655","phase":"PHASE2","title":"Zevalin® First Line in Follicular Lymphoma","status":"UNKNOWN","sponsor":"Charite University, Berlin, Germany","startDate":"2007-10","conditions":"Follicular Lymphoma","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ibritumomab Tiuxetan"],"phase":"phase_3","status":"active","brandName":"Ibritumomab Tiuxetan + Maintenance","genericName":"Ibritumomab Tiuxetan + Maintenance","companyName":"Fondazione Italiana Linfomi - ETS","companyId":"fondazione-italiana-linfomi-ets","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ibritumomab tiuxetan is a radiolabeled monoclonal antibody that targets CD20 on B cells and delivers cytotoxic radiation directly to lymphoma cells. Used for Relapsed or refractory B-cell non-Hodgkin lymphoma, Follicular lymphoma (maintenance therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}